Pooled Efficacy and Safety Profile of Netarsudil Ophthalmic Solution 0.02% in Patients With Open-angle Glaucoma or Ocular Hypertension

PRECIS: In pooled phase III analyses, once-daily netarsudil 0.02% resulted in intraocular pressure (IOP) reduction that was noninferior to twice-daily timolol 0.5%, with minimal treatment-related serious or systemic adverse events (AEs). Ocular AEs were generally tolerable. PURPOSE: The purpose of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Inder P., Fechtner, Robert D., Myers, Jonathan S., Kim, Terry, Usner, Dale W., McKee, Hayley, Sheng, Huan, Lewis, Richard A., Heah, Theresa, Kopczynski, Casey C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647436/
https://www.ncbi.nlm.nih.gov/pubmed/32826769
http://dx.doi.org/10.1097/IJG.0000000000001634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7647436/
https://www.ncbi.nlm.nih.gov/pubmed/32826769
http://dx.doi.org/10.1097/IJG.0000000000001634

Ejemplares similares